# Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy

> **NCT05796271** · PHASE1 · WITHDRAWN · sponsor: **The University of Texas Health Science Center at San Antonio**

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** R-Chop and Roflumilast

## Key facts

- **NCT ID:** NCT05796271
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate funding to begin enrolling subjects
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05796271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05796271, "Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05796271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*